Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3717-3727

  Van Der Meel, Roy ^a   Oliveira, Sabrina ^b,c   Altintas, Isil ^a   Heukers, Raimond ^b   Pieters, Ebel H E ^a   Van Bergen En Henegouwen, Paul M P ^b   Storm, Gert ^a,d   Hennink, Wim E ^a   Kok, Robbert J ^a   Schiffelers, Raymond M ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Combination therapy; Drug targeting and delivery; EGFR; IGF 1R; Liposomes; Nanobody; Nanomedicine

Indexed keywords

AG 538; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LIPOSOME; NANOBODY; PROTEIN KINASE INHIBITOR; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; LIPOSOMES; MALE; MICE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SINGLE-DOMAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887606851     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400212v     Document Type: Article

References (42)

1. Yarden, Y.; Pines, G. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12 (8), 553-563.
2. Petrelli, F.; Borgonovo, K.; Cabiddu, M.; Barni, S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall-cell lung cancer: a meta-analysis of 13 randomized trials. Clin. Lung Cancer 2012, 13 (2), 107-114.
3. Gao, G.; Ren, S.; Li, A.; Xu, J.; Xu, Q.; Su, C.; Guo, J.; Deng, Q.; Zhou, C. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int. J. Cancer 2012, 131 (5), E822-E829.
4. Wheeler, D. L.; Dunn, E. F.; Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7 (9), 493-507.
5. Yee, D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J. Natl. Cancer Inst. 2012, 104 (13), 975-81.
6. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 2012, 12 (3), 159-169.
7. Morgillo, F.; Kim, W. Y.; Kim, E. S.; Ciardiello, F.; Hong, W. K.; Lee, H. Y. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res. 2007, 13 (9), 2795-2803.
8. Guix, M.; Faber, A. C.; Wang, S. E.; Olivares, M. G.; Song, Y.; Qu, S.; Rinehart, C.; Seidel, B.; Yee, D.; Arteaga, C. L.; Engelman, J. A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118 (7), 2609-2619.
9. Buck, E.; Eyzaguirre, A.; Rosenfeld-Franklin, M.; Thomson, S.; Mulvihill, M.; Barr, S.; Brown, E.; O'Connor, M.; Yao, Y.; Pachter, J.; Miglarese, M.; Epstein, D.; Iwata, K. K.; Haley, J. D.; Gibson, N. W.; Ji, Q. S. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68 (20), 8322-8332.
10. Galer, C. E.; Corey, C. L.; Wang, Z.; Younes, M. N.; Gomez-Rivera, F.; Jasser, S. A.; Ludwig, D. L.; El-Naggar, A. K.; Weber, R. S.; Myers, J. N. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2011, 33 (2), 189-198.
11. Dong, J.; Sereno, A.; Aivazian, D.; Langley, E.; Miller, B. R.; Snyder, W. B.; Chan, E.; Cantele, M.; Morena, R.; Joseph, I. B.; Boccia, A.; Virata, C.; Gamez, J.; Yco, G.; Favis, M.; Wu, X.; Graff, C. P.; Wang, Q.; Rohde, E.; Rennard, R.; Berquist, L.; Huang, F.; Zhang, Y.; Gao, S. X.; Ho, S. N.; Demarest, S. J.; Reff, M. E.; Hariharan, K.; Glaser, S. M. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011, 3 (3), 273-288.
12. Shaw, P. H.; Maughan, T. S.; Clarke, A. R. Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse. Br. J. Cancer 2011, 105 (5), 649-657.
13. Cortot, A. B.; Repellin, C. E.; Shimamura, T.; Capelletti, M.; Zejnullahu, K.; Ercan, D.; Christensen, J. G.; Wong, K. K.; Gray, N. S.; Janne, P. A. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013, 73 (2), 834-843.
14. Duncan, R.; Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharmaceutics 2011, 8 (6), 2101-2141.
15. van der Meel, R.; Oliveira, S.; Altintas, I.; Haselberg, R.; van der Veeken, J.; Roovers, R. C.; van Bergen en Henegouwen, P. M.; Storm, G.; Hennink, W. E.; Schiffelers, R. M.; Kok, R. J. Tumor-targeted nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J. Controlled Release 2012, 159 (2), 281-289.
16. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E. B.; Bendahman, N.; Hamers, R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363 (6428), 446-448.
17. Oliveira, S.; Schiffelers, R. M.; van der Veeken, J.; van der Meel, R.; Vongpromek, R.; van Bergen En Henegouwen, P. M.; Storm, G.; Roovers, R. C. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J. Controlled Release 2010, 145 (2), 165-175.
18. Hofman, E. G.; Ruonala, M. O.; Bader, A. N.; van den Heuvel, D.; Voortman, J.; Roovers, R. C.; Verkleij, A. J.; Gerritsen, H. C.; van Bergen En Henegouwen, P. M. EGF induces coalescence of different lipid rafts. J. Cell Sci. 2008, 121 (Pt 15), 2519-2528.
19. Schmitz, K. R.; Bagchi, A.; Roovers, R. C.; van Bergen En Henegouwen, P. M.; Ferguson, K. M. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure 2013, 21 (7), 1214-1224.
20. Roovers, R. C.; Henderikx, P.; Helfrich, W.; van der Linden, E.; Reurs, A.; de Bruine, A. P.; Arends, J. W.; de Leij, L.; Hoogenboom, H. R. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br. J. Cancer 1998, 78 (11), 1407-1416.
21. Altintas, I.; Heukers, R.; van der Meel, R.; Lacombe, M.; Amidi, M.; van Bergen En Henegouwen, P. M.; Hennink, W. E.; Schiffelers, R. M.; Kok, R. J. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J. Controlled Release 2013, 165 (2), 110-118.
22. Rouser, G.; Fkeischer, S.; Yamamoto, A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970, 5 (5), 494-496.
23. Brenner, J. C.; Graham, M. P.; Kumar, B.; Saunders, L. M.; Kupfer, R.; Lyons, R. H.; Bradford, C. R.; Carey, T. E. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010, 32 (4), 417-26.
24. Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1 (3), 1112-1116.
25. Zucker, D.; Marcus, D.; Barenholz, Y.; Goldblum, A. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J. Controlled Release 2009, 139 (1), 73-80.
26. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773 (8), 1263-1284.
27. van der Veeken, J.; Oliveira, S.; Schiffelers, R. M.; Storm, G.; van Bergen En Henegouwen, P. M.; Roovers, R. C. Crosstalk between epidermal growth factor receptor-and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr. Cancer Drug Targets 2009, 9 (6), 748-760.
28. Davison, Z.; de Blacquiere, G. E.; Westley, B. R.; May, F. E. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011, 13 (6), 504-515.
29. Blum, G.; Gazit, A.; Levitzki, A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 2000, 39 (51), 15705-15712.
30. Buck, E.; Gokhale, P. C.; Koujak, S.; Brown, E.; Eyzaguirre, A.; Tao, N.; Rosenfeld-Franklin, M.; Lerner, L.; Chiu, M. I.; Wild, R.; Epstein, D.; Pachter, J. A.; Miglarese, M. R. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 2010, 9 (10), 2652-2664.
31. Zhang, Y. W.; Staal, B.; Essenburg, C.; Su, Y.; Kang, L.; West, R.; Kaufman, D.; Dekoning, T.; Eagleson, B.; Buchanan, S. G.; Vande Woude, G. F. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010, 70 (17), 6880-6890.
32. Choi, E. J.; Ryu, Y. K.; Kim, S. Y.; Wu, H. G.; Kim, J. S.; Kim, I. H.; Kim, I. A. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol. Cancer Res. 2010, 8 (7), 1027-1036.
33. She, Q. B.; Solit, D. B.; Ye, Q.; O'Reilly, K. E.; Lobo, J.; Rosen, N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005, 8 (4), 287-297.
34. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Delivery Rev. 2011, 63 (3), 136-151.
35. van Dongen, G. A.; Braakhuis, B. J.; Leyva, A.; Hendriks, H. R.; Kipp, B. B.; Bagnay, M.; Snow, G. B. Anti-tumor and differentiationinducing activity of N, N-dimethylformamide (DMF) in head-and-neck cancer xenografts. Int. J. Cancer 1989, 43 (2), 285-292.
36. Ruiz van Haperen, V. W.; Veerman, G.; Boven, E.; Noordhuis, P.; Vermorken, J. B.; Peters, G. J. Schedule dependence of sensitivity to 2', 2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem. Pharmacol. 1994, 48 (7), 1327-1339.
37. Talelli, M.; Oliveira, S.; Rijcken, C. J.; Pieters, E. H.; Etrych, T.; Ulbrich, K.; van Nostrum, R. C.; Storm, G.; Hennink, W. E.; Lammers, T. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials 2013, 34 (4), 1255-1260.
38. Coimbra, M.; Isacchi, B.; van Bloois, L.; Torano, J. S.; Ket, A.; Wu, X.; Broere, F.; Metselaar, J. M.; Rijcken, C. J.; Storm, G.; Bilia, R.; Schiffelers, R. M. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int. J. Pharm. 2011, 416 (2), 433-442.
39. Vaneycken, I.; Devoogdt, N.; Van Gassen, N.; Vincke, C.; Xavier, C.; Wernery, U.; Muyldermans, S.; Lahoutte, T.; Caveliers, V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011, 25 (7), 2433-2446.
40. Behdani, M.; Zeinali, S.; Khanahmad, H.; Karimipour, M.; Asadzadeh, N.; Azadmanesh, K.; Khabiri, A.; Schoonooghe, S.; Habibi Anbouhi, M.; Hassanzadeh-Ghassabeh, G.; Muyldermans, S. Generation and characterization of a functional nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol. Immunol. 2012, 50 (1.2), 35-41.
41. Debets, M. F.; Leenders, W. P.; Verrijp, K.; Zonjee, M.; Meeuwissen, S. A.; Otte-Holler, I.; van Hest, J. C. Nanobodyfunctionalized polymersomes for tumor-vessel targeting. Macromol Biosci 2013, 13, 938-945.
42. Van de Broek, B.; Devoogdt, N.; D'Hollander, A.; Gijs, H. L.; Jans, K.; Lagae, L.; Muyldermans, S.; Maes, G.; Borghs, G. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano 2011, 5 (6), 4319-4328.